Get the Stockscreener App
0.677
0.79%
0.00533
After Hours:
.66
-0.017
-2.51%
Salarius Pharmaceuticals Inc stock is traded at $0.677, with a volume of 47,221.
It is up +0.79% in the last 24 hours and down -25.60% over the past month.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
See More
Previous Close:
$0.6717
Open:
$0.64
24h Volume:
47,221
Relative Volume:
0.15
Market Cap:
$1.18M
Revenue:
$4.70M
Net Income/Loss:
$-4.99M
P/E Ratio:
-0.1055
EPS:
-6.42
Net Cash Flow:
$-5.29M
1W Performance:
+12.83%
1M Performance:
-25.60%
6M Performance:
-63.41%
1Y Performance:
-83.42%
1-Day Range:
$0.64
$0.7099
1-Week Range:
$0.5803
$0.722
52-Week Range:
$0.4519
$7.20
Salarius Pharmaceuticals Inc Stock (SLRX) Company Profile
Name
Salarius Pharmaceuticals Inc
Sector
Industry
Phone
346-772-0346
Address
2450 HOLCOMBE BLVD, HOUSTON
Compare SLRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLRX
Salarius Pharmaceuticals Inc
|
0.677 | 1.18M | 4.70M | -4.99M | -5.29M | -6.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Salarius Pharmaceuticals Inc Stock (SLRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-20 | Initiated | Ladenburg Thalmann | Buy |
Salarius Pharmaceuticals Inc Stock (SLRX) Latest News
Decoy Therapeutics to Welcome MIT's Robert Langer to Advisory Board Post-Merger with Salarius (SLRX) | SLRX Stock News - GuruFocus
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board - GlobeNewswire
SLRX stock touches 52-week low at $0.7 amid sharp annual decline - Investing.com Canada
SLRX stock touches 52-week low at $0.7 amid sharp annual decline By Investing.com - Investing.com South Africa
Contrasting Salarius Pharmaceuticals (NASDAQ:SLRX) & ASLAN Pharmaceuticals (NASDAQ:ASLN) - Defense World
Salarius Amends Merger Terms, Faces Nasdaq Compliance Issue - Investing.com India
Salarius Amends Merger Terms, Faces Nasdaq Compliance Issue By Investing.com - Investing.com UK
SLRX stock touches 52-week low at $0.83 amid market challenges By Investing.com - Investing.com South Africa
SLRX stock touches 52-week low at $0.83 amid market challenges - Investing.com Australia
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces Its Novel Inhibitors Show Promising In Silico Activity Against Measles And Related Viruses - MarketScreener
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses - GlobeNewswire
Revolutionary AI Platform Discovers Multi-Target Antiviral in Just 5 Days - Stock Titan
Salarius Pharmaceuticals Advances Merger with Decoy Therapeutics to Enhance Development of Innovative Cancer and Viral Therapeutics - Nasdaq
Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update - GlobeNewswire
Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update - GlobeNewswire Inc.
Salarius Pharmaceuticals Inc. (SLRX) reports earnings - Quartz
Salarius Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Apraxia Treatment Market Size in 7MM is expected to grow at - openPR.com
Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Short Interest Update - Defense World
SLRX stock touches 52-week low at $0.9 amid market challenges - Investing.com
SLRX stock touches 52-week low at $0.9 amid market challenges By Investing.com - Investing.com South Africa
Salarius Pharmaceuticals announces registered share offering By Investing.com - Investing.com South Africa
Salarius Pharmaceuticals announces registered share offering - Investing.com
SLRX stock touches 52-week low at $1.22 amid market challenges - Investing.com Australia
SLRX stock touches 52-week low at $1.22 amid market challenges By Investing.com - Investing.com South Africa
Salarius Pharmaceuticals Inc to Host Earnings Call - ACCESS Newswire
Salarius Pharmaceuticals (NASDAQ:SLRX) Shares Up 0.5% – Still a Buy? - Defense World
What Recent Market Trends Mean for Salarius Pharmaceuticals Inc’s (SLRX) Stock - The News Heater
Salarius resumes trial for MDS and CMML treatment - Investing.com India
Salarius resumes trial for MDS and CMML treatment By Investing.com - Investing.com Australia
Salarius Pharmaceuticals Announces Patient Enrollment to - GlobeNewswire
Breakthrough Cancer Treatment Shows Triple Survival Time: Trial Back on Track - StockTitan
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt - Benzinga
Deal Watch: Bausch Companies Set Hectic Pace At J.P. Morgan With Five Deals - News & Insights
Salarius Pharmaceuticals and Decoy Therapeutics announce merger - MSN
Stock market news: Phio Pharmaceuticals -50.61%, Salarius Pharmaceuticals -28.61% among biggest losers during mid day trading - Business Upturn
Stock market today: Phio Pharmaceuticals -41.48%, Aehr Test Systems -26.86% among biggest losers in early trading - Business Upturn
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Shareholder Alert: Ademi LLP investigates whether Salarius Pharmaceuticals, Inc. is obtaining a Fair Price for its Public Shareholders - Business Wire
Premier of separatist Moldova region says gas cutoff shattered foreign trade - Yahoo! Voices
Biologics Contract Development And Manufacturing Organization (CDMO) Market size to increase by USD 16.32 Billion between 2024 to 2029, Market Segmentation by Type, Product Type, Geography , Technavio - Yahoo Finance
Here’s Why Chimerix, Inc. (CMRX) Is Skyrocketing - Yahoo Finance
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Here’s Why Cidara Therapeutics, Inc. (CDTX) Is Skyrocketing - Yahoo Finance
Here’s Why Solaris Energy Infrastructure, Inc. (SEI) Is Skyrocketing - Yahoo Finance
Houston's Salarius Pharmaceuticals to merge with Gates Foundation-backed co., focus on Covid-19 treatment - The Business Journals
Biogen Offers to Buy Remaining Stake in Sage Therapeutics - Yahoo Finance
Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge - Benzinga
Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On MondayHere's Why - Yahoo Finance
Thermo Fisher Scientific Inc. (TMO): A Bull Case Theory - Yahoo Finance
Stock market news: Phio Pharmaceuticals +296.88%, Salarius Pharmaceuticals +153.67% among top gainers during mid day trading - Business Upturn
Salarius Pharmaceuticals Inc Stock (SLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):